R&D Supercharging clinical development with RWE – with Recursion... Greater availability of real-world data and real-world evidence is rapidly changing the landscape of drug development.
Digital “Data is our currency” – with Ginkgo Datapoints’ John Andros... Successful use of AI is becoming a key differentiator for pharma companies.
Patients How pharma is tackling new direct-to-patient programmes At Reuters Pharma USA, executives from AstraZeneca, Gilead, Kyowa Kirin, and EVERSANA discussed the what, why, and how of direct-to-patient models.
Patients Direct-to-patient is more than just telehealth – with EVERSA... Hear from EVERSANA's Faruk Abdullah in this video interview as he explains why direct-to-patient strategies go beyond telehealth.
Patients New Boehringer US Head Brian Hilberdink talks GLP-1s, DTx an... At Reuters Pharma USA, editor-in-chief Jonah Comstock caught up with Brian Hilberdink, the new head of US human pharma at Boehringer Ingelheim.
Market Access Boehringer US head covers GLP-1s, PBMs, Trump at Reuters USA Brian Hilberdink, Boehringer Ingelheim's new Head of US Human Pharma, fielded questions on a variety of hot topics from the Reuters Pharma USA stage.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face